Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 31, 2014, Pages 11449-11454

  Zuckerman, Jonathan E ^a   Gritli, Ismael ^b   Tolcher, Anthony ^c   Heidel, Jeremy D ^d   Lim, Dean ^e   Morgan, Robert ^e   Chmielowski, Bartosz ^f   Ribas, Antoni ^f   Davis, Mark E ^a   Yen, Yun ^b,e  

^a California Institute of Technology   (United States)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c South Texas Accelerated Research Therapeutics   (United States)

^d Informulate   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DNA proliferation; DNA replication; Dose limiting toxicity; Maximum tolerance dose; Translational medicine

Indexed keywords

ANTINEOPLASTIC AGENT; BICALUTAMIDE; CALAA 01; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HAPLORHINI; HUMAN; HYPONATREMIA; INNATE IMMUNITY; ISCHEMIC COLITIS; LIMIT OF DETECTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG METASTASIS; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; NEPHROTOXICITY; NONHUMAN; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RECTUM CARCINOMA; RNA INTERFERENCE; SINUS BRADYCARDIA; SMALL CELL CARCINOMA; SYSTEMIC THERAPY; UTERINE CERVIX CARCINOMA;

DNA PROLIFERATION; DNA REPLICATION; DOSE LIMITING TOXICITY; MAXIMUM TOLERANCE DOSE; TRANSLATIONAL MEDICINE;

AGED; AGED, 80 AND OVER; ANIMALS; BLOOD COAGULATION; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; DEMOGRAPHY; FEMALE; HAPLORHINI; HUMANS; IMMUNIZATION; KIDNEY; LIVER; MALE; MICE; MIDDLE AGED; NANOPARTICLES; PLATELET COUNT; POLYETHYLENE GLYCOLS; POLYMERS; RATS; RNA, SMALL INTERFERING; SPECIES SPECIFICITY; TREATMENT OUTCOME;

EID: 84905670761     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1411393111     Document Type: Article

References (23)

1. Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for siRNA therapeutics. Nat Mater 12(11):967-977.
2. Davis ME, et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):1067-1070.
3. Tabernero J, et al. (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3(4):406- 417.
4. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm 6(3):659-668.
5. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY (1983) Transferrin receptors in human tissues: Their distribution and possible clinical relevance. J Clin Pathol 36(5):539-545. (Pubitemid 13089724)
6. Zuckerman JE, Ribas A, Davis ME (2011) Reply to Perris, Borghese, and Magro. Pigment Cell Melanoma Res 24:983-985.
7. Shao J, Zhou B, Chu B, Yen Y (2006) Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6(5):409-431. (Pubitemid 44033390)
8. Heidel JD, et al. (2007) Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res 13(7):2207-2215. (Pubitemid 46649891)
9. Rahman MA, et al. (2012) Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Release 159(3):384-392.
10. Bartlett DW, Davis ME (2007) Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 18(2):456-468. (Pubitemid 46493517)
11. Dreher MR, et al. (2006) Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98(5):335-344. (Pubitemid 43338213)
12. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC (2012) Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem Soc Rev 41(7):2971-3010.
13. Zuckerman JE, Choi CHJ, Han H, Davis ME (2012) Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci USA 109(8):3137-3142.
14. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22(3):659-661. (Pubitemid 351348146)
15. Henry SP, Monteith D, Kornbrust DJ, Levin Aa (1997) Effects of intravenous infusion of phosphorothioate oligonucleotides on coagulation, complement activation and hemodynamics. Nucleosides Nucleotides 16(7-9):1673-1676.
16. Robbins M, et al. (2008) Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 19(10):991-999.
17. Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME (2004) Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 22(12):1579-1582. (Pubitemid 40039462)
18. Inaba S, et al. (2012) Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther 20(2):356-366.
19. Heidel JD, et al. (2007) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104(14):5715-5721. (Pubitemid 47175600)
20. Caron WP, et al. (2011) Allometric scaling of pegylated liposomal anticancer drugs. J Pharmacokinet Pharmacodyn 38(5):653-669.
21. Eliasof S, et al. (2013) Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci USA 110(37):15127- 15132.
22. Yoshino Y, Nagaya K, Sekino H, Uchida MK, Suzuki-Nishimura T (1990) Comparison of histamine release induced by synthetic polycations with that by compound 48/80 from rat mast cells. Jpn J Pharmacol 52(3):387-395. (Pubitemid 20090761)
23. Yu RZ, et al. (2002) Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304(1):19-25. (Pubitemid 34492838)